PerkinElmer posts growth in Q2

By staff writers

July 26, 2021 -- PerkinElmer posted revenue and operating income increases in its second quarter 2021 (end-July 4).

For the quarter, the company reported revenue in its Discovery and Analytical Solutions segment of $513 million, compared to $391 million for the same period in 2020. It posted operating income from continuing operations for the segment of $64 million, compared to $39 million for the second quarter of last year, and operating income of $101 million, compared to $57 million in the same period in 2020.

In other PerkinElmer news, the company announced that it will acquire antibody and research reagent manufacturer BioLegend for $5.25 billion.

PerkinElmer to buy Immunodiagnostic Systems
PerkinElmer announced it will acquire U.K. firm Immunodiagnostic Systems Holdings for approximately $155 million. PerkinElmer said the deal will...
PerkinElmer unveils COVID-19 rapid antigen test
PerkinElmer has launched a lateral-flow immunoassay COVID-19 antigen test, a rapid antigen test suitable for mass COVID-19 screening or for diagnosis...
FDA clears PerkinElmer coronavirus test for asymptomatic use
PerkinElmer's New Coronavirus Nucleic Acid Detection kit has received an emergency use authorization from the U.S. Food and Drug Administration (FDA)...
PerkinElmer to buy Oxford Immunotec Global
PerkinElmer plans to acquire Oxford Immunotec Global and that company's infectious disease testing technology in a deal worth $591 million. The purchase...
PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.

Copyright © 2021

Last Updated ls 7/26/2021 3:55:59 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current